High-resolution mass spectrometry measurement of N-terminal carbamylated hemoglobin as a potential marker for chronic diseases with elevated blood urea levels by Fangjun Chen, Priscilla S.-W. Yeung, Carolyn V. Wong, Ruben Y. Luo

“…Blood samples from healthy individuals, CKD patients, and chronic obstructive pulmonary disease (COPD) patients were analyzed. …”
Get full text

Nomograms for Predicting High Hospitalization Costs and Prolonged Stay among Hospitalized Patients with pAECOPD by Nafeisa Dilixiati, Mengyu Lian, Ziliang Hou, Jie Song, Jingjing Yang, Ruiyan Lin, Jinxiang Wang

“…This study aimed to develop nomograms to predict high hospitalization costs and prolonged stays in hospitalized acute exacerbations of chronic obstructive pulmonary disease (AECOPD) patients with community-acquired pneumonia (CAP), also known as pAECOPD. …”
Get full text

MicroRNA-101-3p Suppresses mTOR and Causes Mitochondrial Fragmentation and Cell Degeneration in COPD by Lei Fang, Xinggang Wang, Ming Zhang, Petra Khan, Michael Tamm, Michael Roth

“…Cigarette smoke is assumed to cause the loss of airway wall structure in chronic obstructive pulmonary disease (COPD) by reducing airway smooth muscle cell (ASMC) function. …”
Get full text

Cigarette Smoke Suppresses the Surface Expression of c-kit and FcεRI on Mast Cells by M. E. Givi, B. R. Blokhuis, C. A. Da Silva, I. Adcock, J. Garssen, G. Folkerts, F. A. Redegeld, E. Mortaz

“…Chronic obstructive pulmonary disease (COPD) is a multicomponent disease characterized by emphysema and/or chronic bronchitis. …”
Get full text

Cost–consequence analysis of COPD treatment according to NICE and GOLD recommendations compared with current clinical practice in the UK by Jennifer K Quint, Helene Vioix, Toby Capstick, Sue Langham, Jennifer Cook, Antony Wright, Shamika de Silva

“…Objectives The objective of this study was to model the clinical and economic impact of adapting current clinical practice in the management of patients with chronic obstructive pulmonary disease (COPD) to treatment according to national and international guideline recommendations.Design Treatment mapping was undertaken to hypothetically redistribute patients from current clinical practice, representing actual prescribing patterns in the UK, to an alternative recommendation-based treatment scenario, representing prescribing in accordance with either National Institute for Health and Care Excellence (NICE) guidance [NG115] or Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020 strategy.Setting Primary care practices in the UK (1-year time horizon).Participants Adults with COPD undergoing long-acting inhaler maintenance therapy in the UK (N=1 067,531).Interventions Inhaler maintenance therapy.Outcome measures Costs and clinical outcomes (type of treatment, rates of moderate and/or severe exacerbations, and mild-to-moderate and/or severe pneumonia events) were modelled for the two alternative pathways.Results Compared with current clinical practice, treating patients according to NICE guidance resulted in an estimated annual reduction in expenditure of £46.9 million, and an estimated annual reduction in expenditure of over £43.7 million when patients were treated according to GOLD 2020 strategy. …”
Get full text

Progress of CCL20-CCR6 in the airways: a promising new therapeutic target by Ya -Jing Li, Wan-Li Geng, Chen-Chen Li, Jia-Hao Wu, Fei Gao, Yong Wang

“…Within the respiratory system, CCL20-CCR6 demonstrates heightened expression in conditions such as allergic asthma, chronic airway inflammation, non-small cell lung cancer (NSCLC), chronic obstructive pulmonary disease (COPD), and other respiratory diseases, which is conducive to the inflammatory mediators recruitment and tumor microenvironment remodeling. …”
Get full text

Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology by Elena Carmona-Rocha, Lluís Rusiñol, Lluís Puig

“…Roflumilast is a PDE4 inhibitor that was approved by the FDA and the EMA as an oral treatment of chronic obstructive pulmonary disease. Since patent expiration, several generic formulations of oral roflumilast have become available, and various studies have documented its off-label use in psoriasis and other dermatological conditions such as hidradenitis suppurativa, recurrent oral aphthosis, nummular eczema, lichen planus, and Behçet’s disease. …”
Get full text

Acute Deterioration of Pulmonary Arterial Hypertension (PAH) in a Patient with Neurofibromatosis Type 1 (NF1) by Seiya Tanaka, Fuko Kawahara, Taro Miyamoto, Satoshi Tsurusaki, Yoshihito Sanuki, Kiyoshi Ozumi, Takashi Harada, Hiromi Tasaki

“…A 56-year-old woman was diagnosed as having chronic obstructive pulmonary disease with heavy smoking. Mild pulmonary hypertension (mean pulmonary arterial pressure: 31 mmHg) was detected at the first visit. …”
Get full text

Regional risk factors associated with adverse outcomes of COVID-19 infection among the older adult: A systematic review and meta-analysis by Olunike Rebecca Abodunrin, Mobolaji Timothy Olagunju, Xinyi Huang, Jianming Wang, Zhibin Hu, Chong Shen

“…Key factors include old age (above 65 years), male gender, symptoms such as fever and dyspnea, and comorbidities like dementia, chronic obstructive pulmonary disease (COPD), chronic heart disease, hypertension, chronic kidney disease, and malnutrition. …”
Get full text

Dysregulation of Vascular Endothelial Progenitor Cells Lung-Homing in Subjects with COPD by Brittany M. Salter, Fizza Manzoor, Suzanne Beaudin, Melanie Kjarsgaard, Parameswaran Nair, Gail M. Gauvreau, Roma Sehmi

“…Chronic obstructive pulmonary disease (COPD) is characterized by fixed airflow limitation and progressive decline of lung function and punctuated by occasional exacerbations. …”
Get full text

Assessing the Clinical and Functional Status of COPD Patients Using Speech Analysis During and After Exacerbation by Mayr W, Triantafyllopoulos A, Batliner A, Schuller BW, Berghaus TM

“…Wolfgang Mayr,1,* Andreas Triantafyllopoulos,2,3,* Anton Batliner,2,3 Björn W Schuller,2– 5 Thomas M Berghaus1,6 1Department of Cardiology, Respiratory Medicine and Intensive Care, University Hospital Augsburg, Augsburg, Germany; 2Chair of Health Informatics (CHI), Department of Clinical Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; 3Munich Center for Machine Learning (MCML), Munich, Germany; 4Group on Language Audio, & Music (GLAM), Imperial College, London, UK; 5Munich Data Science Institute (MDSI), Munich, Germany; 6Medical Faculty, Ludwig Maximilians University of Munich, Munich, Germany*These authors contributed equally to this workCorrespondence: Wolfgang Mayr, Department of Cardiology, Respiratory Medicine and Intensive Care, University Hospital Augsburg, Stenglinstrasse 2, Augsburg, D-86156, Germany, Email wolfgang.mayr@uk-augsburg.de Andreas Triantafyllopoulos, Chair of Health Informatics, Department of Clinical Medicine, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Straße 22, Munich, 81675, Germany, Email andreas.triantafyllopoulos@tum.deBackground: Chronic obstructive pulmonary disease (COPD) affects breathing, speech production, and coughing. …”
Get full text

EFFORTS IN CONTROLLING COAL DUST HAZARDS IN THE STOCKPILE AREA OF A STEAM POWER PLANT (PLTU) by Alifiah Rizky Rosydah, Y. Denny Ardyanto Wahyudiono, Ahmad Imaduddin, Dani Nasirul Haqi, Meirina Ernawati

“…The smaller the particle size, the more harmful effects it can have on human health, such as bronchitis, decreased lung function, Chronic Obstructive Pulmonary Disease (COPD), Coal Worker's Pneumoconiosis (CWP), and other respiratory diseases. …”
Get full text

Assessing the impact of long-term inhaled corticosteroid therapy on patients with COVID-19 and coexisting chronic lung disease: A multicenter retrospective cohort study by Adela Pina Belmonte, Manuel Madrazo, Laura Piles, Manuel Rubio-Rivas, Lucía de Jorge Huerta, María Gómez Antúnez, Juan Francisco López Caleya, Francisco Arnalich Fernández, Martin Gericó-Aseguinolaza, Paula Maria Pesqueira Fontan, Nicolás Rhyman, Marina Prieto Dehesa, Juan Luis Romero Cabrera, Gema María García García, Gonzalo García-Casasola, Ane Labirua-Iturburu Ruiz, Francisco Javier Carrasco-Sánchez, Sara Martínez Hernández, Maria de los Reyes Pascual Pérez, José López Castro, José Luis Serrano Carrillo de Albornoz, José F. Varona, Ricardo Gómez-Huelgas, Juan-Miguel Antón-Santos, Carlos Lumbreras-Bermejo

“…# Background Patients with chronic lung disease (CLD), such as asthma or chronic obstructive pulmonary disease, were expected to have an increased risk of clinical manifestations and severity of COVID-19. …”
Get full text

Demographic and Clinical Presentation of Hospitalised Patients with SARS-CoV-2 During the First Omicron Wave by Mehool Patel, Elizabeth Aitken

“…Common COVID-19 presentations included delirium, falls, seizures, chronic obstructive pulmonary disease, and antenatal problems. Overall, 13.7% (76/553) patients died and 4.7% (26/553) were directly attributable to COVID-19. …”
Get full text

Neuropeptides SP and CGRP Diminish the Moraxella catarrhalis Outer Membrane Vesicle- (OMV-) Triggered Inflammatory Response of Human A549 Epithelial Cells and Neutrophils by Daria Augustyniak, Justyna Roszkowiak, Izabela Wiśniewska, Jacek Skała, Daiva Gorczyca, Zuzanna Drulis-Kawa

“…Moraxella catarrhalis is one of the leading infectious agents responsible for inflammatory exacerbation in chronic obstructive pulmonary disease (COPD). Since the airway inflammation in COPD is connected with activation of both epithelial cells and accumulated neutrophils, in this study we determined the in vitro effects of neuropeptides on the inflammatory potential of these cells in response to M. catarrhalis outer membrane vesicle (OMV) stimulant. …”
Get full text

Clinical Predictors of Hospital-acquired Pneumonia Associated with Acute Ischemic by Alexis Suárez Quesada, Ezequiel López Espinosa, Noelsis García Verdecia, Miguel Ángel Serra Valdés

“…The following independent factors were identified: Glasgow Coma Scale ≤ 11 (OR: 26.099; 95 % CI 7.164-85.075), history of chronic obstructive pulmonary disease (OR: 8.896; 95 % CI 1.203-65.779), dysphagia (OR: 7.652; 95 % CI 2.369- 24.720), history of heart failure (OR: 4.583; 95 % CI 1.240- 16.932) and dysarthria/severe motor aphasia (OR: 4.222; 95 % CI 1.374- 12.975). …”
Get full text

Development and validation of a novel AI-derived index for predicting COPD medical costs in clinical practice by Guan-Heng Liu, Chin-Ling Li, Chih-Yuan Yang, Shih-Feng Liu

“…Background: Chronic Obstructive Pulmonary Disease (COPD) is a major contributor to global morbidity and healthcare costs. …”
Get full text

NLRP3 is a BMI-independent mediator of stable COPD by Yonca Gungor, Selin Ercan, Saliha Selin Özuygur Ermiş, Yiğit Kozalı, Gizem Kursunluoglu, Ceyda Sahan, Aylin Ozgen Alpaydin, Hulya Ayar Kayali

“…Abstract Purpose The inflammatory response in animal models of chronic obstructive pulmonary disease (COPD) is activated by the NLR-family-pyrin-domain-containing-3 (NLRP3) inflammasome pathway, which is also known to play a role in obesity-related inflammation. …”
Get full text

Malondialdehyde in Exhaled Breath Condensate as a Marker of Oxidative Stress in Different Pulmonary Diseases by M. L. Bartoli, F. Novelli, F. Costa, L. Malagrinò, L. Melosini, E. Bacci, S. Cianchetti, F. L. Dente, A. Di Franco, B. Vagaggini, P. L. Paggiaro

“…We measured MDA levels in EBC in a large number of patients (N=194) with respiratory diseases: asthma (N=64), bronchiectasis (BE, N=19), chronic obstructive pulmonary disease (COPD, N=73), idiopathic pulmonary fibrosis (IPF, N=38). …”
Get full text

Comprehensive Analysis of Transcriptome Sequencing Data in the Lung Tissues of COPD Subjects by Woo Jin Kim, Jae Hyun Lim, Jae Seung Lee, Sang-Do Lee, Ju Han Kim, Yeon-Mok Oh

“…Background and Objectives. Chronic obstructive pulmonary disease (COPD) is a complex disease characterized by airflow limitation. …”
Get full text